 WAKEFIELD, Mass., April 05, 2021 GLOBE NEWSWIRE -- Innovation Pharmaceuticals OTCQB:IPIX the Company, a clinical stage biopharmaceutical company, today announced that an independent Data Monitoring Committee DMC completed its scheduled review of interim safety data in the Companys randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients see NCT04784897. 